Common and Less Common Side Effects of Fluoxetine
Fluoxetine commonly causes gastrointestinal symptoms (nausea, vomiting, diarrhea) and activating effects (insomnia, anxiety, nervousness), with most of these side effects resolving within the first few weeks of treatment 1, 2.
Most Common Side Effects (Occurring in >5% of Patients)
Based on FDA labeling and clinical guideline data, the most frequently reported adverse events include 1, 2:
- Gastrointestinal effects: Nausea (most common reason for discontinuation), vomiting, diarrhea, decreased appetite/anorexia
- Neuropsychiatric effects: Insomnia (28-33% in OCD/bulimia trials), anxiety/nervousness (12-16%), headache, dizziness, somnolence
- Sexual dysfunction: Present but likely underreported; fluoxetine has lower rates than paroxetine but higher than bupropion 1
- Weight changes: Weight loss is more common than weight gain, particularly in the first 12 weeks 3
Important Clinical Context
Most activating and gastrointestinal side effects decrease significantly over time - studies show that all common adverse events occurring in >5% of patients early in treatment become significantly less frequent with continued therapy over 6 months 4. This is critical counseling information: patients experiencing nausea, insomnia, or nervousness in weeks 1-4 will likely see resolution without intervention.
Less Common but Clinically Significant Side Effects
Serious Adverse Events to Monitor
Suicidality: SSRIs including fluoxetine are associated with increased risk of nonfatal suicide attempts (OR 1.57-2.25 compared to placebo), though not completed suicide 1. This warrants close monitoring, particularly in the first weeks of treatment.
Bleeding risk: Fluoxetine increases bleeding events ranging from ecchymoses to life-threatening hemorrhages, especially when combined with NSAIDs, aspirin, or anticoagulants 2.
Hyponatremia/SIADH: Can occur with serum sodium <110 mmol/L; elderly patients and those on diuretics are at higher risk. Presents with headache, confusion, weakness, unsteadiness, and in severe cases, seizures or coma 2.
Seizures: Reported in 0.1-0.2% of patients in controlled trials 2.
Activation of mania/hypomania: Occurs in 0.1-0.8% depending on indication; most common reason for discontinuation in pediatric trials (1.8%) 2.
Other Notable Side Effects
- Abnormal bleeding (ecchymoses, epistaxis, petechiae)
- Serotonin syndrome (rare but potentially life-threatening when combined with other serotonergic agents)
- Cardiovascular effects (generally minimal compared to other antidepressants)
- Dry mouth (2.71-52.17% frequency, though less common than with tricyclics) 5
- Tremor and extrapyramidal symptoms (akathisia, dyskinesias) 6
Key Clinical Pitfalls to Avoid
Don't switch medications prematurely: Early side effects (nausea, insomnia, anxiety) typically resolve by week 4-6 without intervention 4. Counsel patients to expect this timeline.
Monitor weight in underweight patients: While fluoxetine causes weight loss on average (2-3 kg, particularly at doses ≥60 mg/day), this may be problematic in underweight depressed or bulimic patients 2, 3.
Drug interactions via CYP2D6 inhibition: Fluoxetine's long half-life and enzyme inhibition increase interaction potential, particularly with TCAs, where accumulation can occur for weeks after fluoxetine discontinuation 2, 7.
No withdrawal syndrome: Unlike other SSRIs, fluoxetine's long half-life (4-6 days for parent compound, 4-16 days for active metabolite) essentially eliminates withdrawal phenomena 7.
The FDA label emphasizes that nausea and vomiting are the most common reasons for treatment discontinuation in efficacy studies 2, making early patient education about transient side effects critical for treatment adherence.